torl-1-23
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 15, 2021 (NCT05103683)
Timeline
Indications
Mechanism of action
- CLDN6Immunity, passive
CLDN6 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06690775 | Phase 2 | Nov 20, 2024 | European Network for Gynaecological Oncological Trial, University of California, Los Angeles |
| NCT05103683 | Phase 1 | Nov 15, 2021 | Translational Research in Oncology, University of California, Los Angeles |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, Los Angeles | Academic/Hospital | 2 | 2 | 2 | 2021 |
| European Network for Gynaecological Oncological Trial | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Translational Research in Oncology | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1